ANVS
Annovis Bio, Inc.
1W: +3.6%
1M: +8.3%
3M: -27.9%
YTD: -28.5%
1Y: +42.6%
3Y: -83.5%
5Y: -92.3%
$2.60
-0.07 (-2.62%)
After Hours: $2.40 (-0.20, -7.69%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$51.2M
52W Range1.11-5.5
Volume658,992
Avg Volume427,347
Beta1.31
Dividend—
Analyst Ratings
Company Info
CEOMaria L. Maccecchini
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2020-01-29
Websiteannovisbio.com
1055 Westlakes Drive
Malvern, PA 19312
US
Malvern, PA 19312
US
610 727 3913
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Latest News
Annovis Bio GAAP EPS of -$1.40
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Annovis Bio (NYSE:ANVS) Stock Price Down 8.5% – What’s Next?
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hoffman Michael B | P-Purchase | 30,000 | $4.34 | 2025-12-08 |
| Hoffman Michael B | P-Purchase | 15,000 | $4.24 | 2025-12-08 |
| Hoffman Michael B | P-Purchase | 28,096 | $4.15 | 2025-11-24 |
| Hoffman Michael B | P-Purchase | 415 | $4.14 | 2025-11-24 |
| Hoffman Michael B | P-Purchase | 9,200 | $3.85 | 2025-11-24 |